Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to include new clinical trial identifiers and drug information, specifically regarding the combination of pembrolizumab and tazemetostat for treating advanced urothelial carcinoma. Additionally, the trial's revision date has been updated to reflect the latest version.SummaryDifference57%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe page has been updated with new dates and a revised version of the study documents provided by the National Cancer Institute, indicating a change in the available information.SummaryDifference0.5%
- Check44 days agoChange DetectedThe page has updated the hospital name to Mercy Hospital Pittsburg and removed the previous hospital name, Ascension Via Christi - Pittsburg. Additionally, several dates have been changed, indicating a shift in scheduling or availability.SummaryDifference0.5%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.